Alnylam (ALNY) Pharmaceuticals announced that it has commenced a private offering of $500M aggregate principal amount of convertible senior notes due 2028 to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam price target raised to $470 from $450 at BMO Capital
- Alnylam’s TRITON-CM Study: A Potential Breakthrough in Cardiomyopathy Treatment
- Alnylam’s Vutrisiran Study Advances in Treating Rare Cardiomyopathy
- Cautious Hold Rating for Alnylam Pharma Amid Uncertain Efficacy of Zilebesiran in KARDIA-3 Trial
- Alnylam price target raised to $583 from $527 at Citi